Evidence map›Paper›PMID 34486814›Full record

ArticleESC heart failure2021

Myocardial ultrastructure can augment genetic testing for sporadic dilated cardiomyopathy with initial heart failure.

Tsunenori Saito, Naoko Saito Sato, Kosuke Mozawa, Akiko Adachi, Yoshihiro Sasaki, Kotoka Nakamura, Eiichiro Oka, Toshiaki Otsuka, Eitaro Kodani, Kuniya Asai and 3 more

Open access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. OPA1, a molecular regulator of dilated cardiomyopathy.Journal of cellular and molecular medicine · 2023
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Tsunenori SaitoSmidt Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA.ORCID 0000-0002-8214-2736
Naoko Saito SatoDepartment of Neurology, Japanese Red Cross Medical Center, Tokyo, Japan.
Kosuke MozawaDepartment of Cardiovascular Medicine, Nippon Medical School Graduate School, Tokyo, Japan.
Akiko AdachiDivision of Morphological and Biomolecular Research, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Yoshihiro SasakiDivision of Morphological and Biomolecular Research, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Kotoka NakamuraSmidt Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA.
Eiichiro OkaDepartment of Cardiovascular Medicine, Nippon Medical School Graduate School, Tokyo, Japan.
Toshiaki OtsukaDepartment of Hygiene and Public Health, Nippon Medical School Graduate School, Tokyo, Japan.
Eitaro KodaniDepartment of Internal Medicine and Cardiology, Nippon Medical School Tama Nagayama Hospital, Tokyo, Japan.
Kuniya AsaiIntensive Care Unit, Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan.
Kyoichi MizunoDepartment of Cardiovascular Medicine, Nippon Medical School Graduate School, Tokyo, Japan.
Wataru ShimizuDepartment of Cardiovascular Medicine, Nippon Medical School Graduate School, Tokyo, Japan.
Roberta A GottliebSmidt Heart Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA.
Nippon Medical School · JPCedars-Sinai Medical Center · USChiba Hokusou Hospital · JPJapanese Red Cross Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe aim of the present study was to consider whether the ultrastructural features of cardiomyocytes in dilated cardiomyopathy can be used to guide genetic testing. METHODS AND

resultsEndomyocardial biopsy and whole-exome sequencing were performed in 32 consecutive sporadic dilated cardiomyopathy patients [51.0 (40.0-64.0) years, 75% men] in initial phases of decompensated heart failure. The predicted pathogenicity of ultrarare (minor allele frequency ≤0.0005), non-synonymous variants was determined using the American College of Medical Genetics guidelines. Focusing on 75 cardiomyopathy-susceptibility and 41 arrhythmia-susceptibility genes, we identified 404 gene variants, of which 15 were considered pathogenic or likely pathogenic in 14 patients (44% of 32). There were five sarcomeric gene variants (29% of 17 variants) found in five patients (16% of 32), involving a variant of MYBPC3 and four variants of TTN. A patient with an MYBPC3 variant showed disorganized sarcomeres, three patients with TTN variants located in the region encoding the A-band domain showed sparse sarcomeres, and a patient with a TTN variant in encoding the I-band domain showed disrupted sarcomeres. The distribution of diffuse myofilament lysis depended on the causal genes; three patients with the same TMEM43 variant had diffuse myofilament lysis near nuclei (P = 0.011), while two patients with different DSP variants had lysis in the peripheral areas of cardiomyocytes (P = 0.033).

conclusionsDerangement patterns of myofilament and subcellular distribution of myofilament lysis might implicate causal genes. Large-scale studies are required to confirm whether these ultrastructural findings are related to the causative genes.

Indexed as

Cardiomyopathy, DilatedHeart FailureMyocardiumAdultCarrier ProteinsConnectinDesmoplakinsFemaleGenetic TestingHumansMaleMiddle AgedMyofibrilsMyosin Binding Protein CSarcomeresCarrier ProteinsConnectinDesmoplakinsDSP protein, humanMyosin Binding Protein CTTN protein, humanCausative gene variantsDilated cardiomyopathyElectron microscopyInitial decompensated heart failureMyofilament changesWhole-exome analysis

Identifiers

PMID34486814
PMCPMC8712817
OpenAlexW3196891959

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.